<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03244423</url>
  </required_header>
  <id_info>
    <org_study_id>IRB0000879560</org_study_id>
    <nct_id>NCT03244423</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Cyanotic Heart Defects</brief_title>
  <official_title>Tranexamic Acid in Cyanotic Heart Defects: a Risk-benefit Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of antifibrinolytic agents such as to reduce blood loss in congenital cardiac surgery
      has been described in many studies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 patients in each one of the three groups; In control group will receive normal saline,
      Intravenous Tranexamic acid group received 50 mg / kg intravenousely followed by of 1
      mg/kg/hr.for six hours. The topical Tranexamic acid group will have 50 mg / kg of tranexamic
      poured into the pericoredial cavity. in the first 24 hours we will measure the total blood
      loss and transfusion requirements. Complate blood picture and coagulation studies will be
      recorded. the occurrence of re-exploration for excess bleeding, or adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative blood loss</measure>
    <time_frame>within the first 24 hours</time_frame>
    <description>Blood loss will be measured within first 24 hr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total blood transfusion</measure>
    <time_frame>within the first 24 hours</time_frame>
    <description>ml/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the interval from protamine to skin closure</measure>
    <time_frame>within the first 24 hours</time_frame>
    <description>the interval from protamine to skin closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the length of ICU stay</measure>
    <time_frame>within the first month</time_frame>
    <description>by days</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Postoperative Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In control group will receive normal saline,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline at induction</intervention_name>
    <description>0.5 ml/kg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline infusion</intervention_name>
    <description>1ml/kg/hr. during surgery for six hours</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous tranexamic acid</intervention_name>
    <description>50 mg/kg</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion tranexamic acid</intervention_name>
    <description>1mg/kg/hr infusionfor 6 hours</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical tranexamic acid</intervention_name>
    <description>50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical normal saline</intervention_name>
    <description>2 ml/kg into the pericardial cavity before sternal closure</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        2 to 12 years cyanotic cardiac disease with cardio pulmonary bypass

        Exclusion Criteria:

        Previous cardiac surgery any operation within 48 hr., previous inotropes or mechanical
        vention aprotinin exposure Liver or renal impairment Coagulation or hemostatic dysfunction
        within the last 7 days before surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sayed k Abd-Elshafy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate profossor of anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <zip>74111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sayed Kaoud Abd-Elshafy</investigator_full_name>
    <investigator_title>Associate Profossor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Cyanotic heart disease</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Postoperative blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>UNDECIDED</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

